Can-Fite BioPharma (CANF) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Can-Fite BioPharma Ltd. has received a patent allowance in Australia for its oral anti-obesity drug Namodenoson, which has demonstrated a promising safety profile. The patent, valid until 2040, covers methods of treating obesity by increasing adiponectin hormone levels to reduce body fat. This advancement positions Can-Fite in the lucrative global obesity treatment market, valued at $12 billion in 2023.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
